Improving vascular health: are pills the answer? by Smeeth, Liam & Hemingway, Harry
Smeeth, L; Hemingway, H (2012) Improving vascular health: are pills
the answer? BMJ (Clinical research ed), 344. e3802. ISSN 0959-8138
Downloaded from: http://researchonline.lshtm.ac.uk/55985/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial
http://creativecommons.org/licenses/by-nc/2.5/
Improving vascular health: are pills the answer?
Lowering the statin treatment threshold raises important questions
LiamSmeeth professor of clinical epidemiology1, Harry Hemingway professor of clinical epidemiology2
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Guidelines from the National Institute for Health and Clinical
Excellence,1 the United States,2 and Europe3 recommend statins
for people with cardiovascular disease and for those at high risk
of developing disease on the basis of an individual risk
assessment. Although there has been much debate about the
optimal risk assessment tool, surprisingly, the risk threshold
above which statins are recommended has been less hotly
debated. A risk of developing cardiovascular disease of greater
than 20% over 10 years—or greater than 10% over five
years—is widely used as the cut-off point for prescribing statins.
The results of a recent meta-analysis of data from the Cholesterol
Treatment Trialists Collaborators directly challenges the
consensus over this threshold.4
Statins reduce the relative risk of major vascular events by
around 20% per 1 mmol/L reduction in low density
lipoprotein-cholesterol—the typical effect on lipids produced
by a low to moderate dose of statin. The striking finding from
the new meta-analysis is that the established beneficial effects
were seen across a broad spectrum of vascular risk, including
people with a five year risk of vascular disease of less than 5%,
well below the current threshold for statin treatment. Therefore,
people at low to medium risk of disease, who are seldom
currently prescribed a statin, may be missing out on a treatment
that has been proved to reduce the incidence of future vascular
events. Should clinical guidelines now be changed and statins
recommended for a larger proportion of the population?
We suggest four factors that warrant detailed consideration
before such a revolutionary change in guidance is made. Firstly,
cost is a consideration. When initially shown to be effective,
statins had 10 year patents and were expensive. Even though
relative measures of benefit (such as the rate ratio) are similar
across different groups, absolute measures of benefit (such as
numbers of events prevented) vary by baseline risk. It is cheaper
to prevent one heart attack by treating 100 people at very high
risk of vascular disease than by treating 1000 people at low risk.
However, as patents expire, cheap generic versions of statins
have become available, including most recently atorvastatin.5
Although it may be relatively cheap to widen the use of statins
use now, a rigorous cost-effectiveness analysis of this approach
is yet to be completed.
Secondly, statins cause harms. Myopathy, and the more serious
rhabdomyolysis, are important, if uncommon, adverse effects
(0.1/1000 people treated for a year or less).6 7 Statins increase
the risk of haemorrhagic stroke,4 although the numbers of
ischaemic strokes prevented outweighs the increased risk of
haemorrhagic stroke. There has been great concern that statins
may increase the risk of diabetes.8A small increased risk seems
likely, but again, the known benefits of statins on vascular
outcomes probably outweigh this risk in all groups studied so
far. Previous concerns that statins may increase the risk of cancer
have been contradicted by evidence from large scale
observational studies and trials.7 9 However, the potential for
increased rates of harm with increased statin use cannot be
ignored, and ongoing vigilance for adverse effects is needed.
A third important factor relevant to any discussion of widening
the use of statins is the viewpoint of the patient, and unanswered
questions abound. For patients to decide whether or not to take
statins more information is needed on outcomes that are relevant
to patients. A patient may ask, “Will statins extend my life?”
This intuitive measure of impact is rarely reported and may give
surprising results. For example, even among high risk patients
undergoing coronary artery bypass grafting compared with
medical therapy, surgery extended survival at 10 years by only
about 35 weeks.10 Extending life by a moderate amount may be
important for some patients but not for others. Do patients want
to delay vascular events? The answer is probably “yes.”
However, death is inevitable and when it comes some people
may prefer a sudden fatal vascular event to a more drawn out
alternative. Do patients on lifelong statin treatment have better
quality of life? We don’t know for sure.
Lastly, why take pills to treat the ills of society? Vascular events
occur largely because of the consequences of industrialised
living associated with poor diet, low levels of exercise, and
smoking. These are (potentially) modifiable factors. Sustainable
improvements in human health—not restricted to vascular
disease and accessible to rich and poor alike—could be achieved
by improving diets, encouraging physical activity, and reducing
smoking. The alternative scenario—of whole populations taking
a daily tablet to mitigate against unhealthy lifestyles—is far
from attractive. Even the consideration of this option may
suggest that the medical profession is losing its way in efforts
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to allow people to live healthier longer lives. If we developed
a tablet that prevented the adverse effects of smoking, would
we advocate widespread consumption, forgetting that a better
aim would be to stop people smoking in the first place?
Evidence that a drug treatment reduces the relative risk for
vascular events is noteworthy but not sufficient to warrant
revising current treatment thresholds. There is a danger that the
quest for a healthier world is replaced by a quest to get more
and more people taking tablets.
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